lifestyle.capitolhilltimes.com

Polpharma Biologics and MS Pharma Sign Licensing Agreements for Proposed Vedolizumab (PB016), Ocrelizumab (PB018) and Guselkumab (PB019) Biosimilars

Written by

Polpharma Biologics and MS Pharma Sign Licensing Agreements for Proposed Vedolizumab (PB016), Ocrelizumab (PB018) and Guselkumab (PB019) Biosimilars – NEWSnet – News… as it used to be

More Press Releases

April 1, 2026

Impact Senior Living Expands in Florida with Three More Communities

April 1, 2026

Rebillia and Global Payments Join Forces to Power AI-Subscription Billing

April 1, 2026

When Your Future Is on the Line: California Criminal Defense and Personal Injury Representation in 2026 – The Law Offices of Patrick S. Aguirre

April 1, 2026

Frontier Medicines Announces Exclusive Licensing Agreement for FMC-220, a First-in-Class Covalent p53 Y220C Activator, with LG Chem, Ltd.